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Summary
Background In patients with multiple endocrine neoplasia type
1 (MEN-1), pancreaticoduodenal (PD) neuroendocrine tumours
(NETs) are associated with early mortality, yet the best treat-
ment strategy remains uncertain.
Aim To assess patient important outcomes (mortality and
metastasis) of PD-NETs and predictors of outcomes in patients
with MEN-1.
Methods Retrospective cohort of patients with MEN-1 who
attended the Mayo Clinic, Rochester, MN from 1997 to 2014.
Results We identified 287 patients with MEN-1; 199 (69%)
patients had 217 PD-NETs. Among those with a PD-NETs, 129
(65%) had surgery of which 90 (70%) had their primary surgery
performed at Mayo Clinic. The median postoperative follow-up
was 8 years during which 13 (14%) patients died. The mean
(standard deviation) age of death was 51 (9) years. Tumour
size, metastasis at surgery or tumour type were not predictive of
mortality, but for every year older at surgery, the odds of metas-
tasis increased by 6%. Surgery was not performed in 70 (35%)
patients. Among those who were observed/medically managed
without known metastatic disease, mean tumour growth was
002 cm/year (range, 013–04 cm/year). Four patients (7%)
died at a median age of 77 (range, 51–89) years.
Conclusion PD-NETs are common in patients with MEN-1
and are associated with early mortality even after surgical inter-
vention. Active surveillance is a viable option in nonaggressive
PD-NETs, although definitive factors identifying such patients
are lacking. Therefore, counselling regarding risks and benefits
of current treatment options remains integral to the care of
patients with MEN-1.
(Received 3 August 2016; finally revised 10 October 2016; accepted
19 October 2016)
Introduction
Multiple endocrine neoplasia type 1 (MEN-1) is a rare autoso-
mal dominant disorder due to a germline mutation of MENIN
on chromosome 11q13.1,2 Loss of this tumour suppressor gene
may lead to the development of parathyroid, pancreaticoduode-
nal and pituitary tumours and less commonly bronchial, thymic
and adrenal tumours as well as cutaneous lesions.3,4 While
parathyroid tumours, in patients with MEN-1, are the most
common manifestation and are associated with morbidity, pan-
creaticoduodenal (PD) neuroendocrine tumours (NETs) pose
the greatest mortality risk.5–7
PD-NETs occur in 70–80% of patients with MEN-1 and may
be classified as nonfunctional or functional tumours (e.g. gastri-
noma, insulinoma, vasoactive intestinal polypeptide [VIP]
secreting tumour [VIPoma] or glucagonoma) depending on the
presence or absence of a hormonal syndrome.8,9 Historically,
death in patients with MEN-1 was attributed to the conse-
quences of excess gastric acid secretion including gastrointestinal
bleeds and ulceration.10,11 However, with the development of
effective medical therapy to reduce gastric acid secretion, meta-
static PD-NETs have now become the leading cause of
death.6,12,13
Although the ideal treatment strategy for PD-NETs is uncer-
tain, it is clear that the overall goal is to control symptoms and
disease burden without any detrimental effect on the quality of
life.9 However, there is paucity of data to help clinicians identify
the exact time in which the benefits of treatment (surgical or
medical) outweigh the possible risks. In fact, researchers have
been unable to find a genotype/phenotype correlation and mark-
ers of aggressive disease (rapid growth and or malignant poten-
tial) remain elusive.14–17 Moreover, there is conflicting evidence
to suggest that metastases are more likely to occur with larger
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tumours.18,19 To address this knowledge gap, we describe the
natural history of a large cohort of patients with MEN-1 and
PD-NETs managed at a single institution and assessed patient
important outcomes such as mortality, predictors of mortality
and metastasis among those who were managed with active
surveillance or surgically.
Methods
Following approval from the Mayo Foundation Institutional
Review Board, we performed a retrospective analysis of patients
with a diagnosis of MEN-1 (International Classification of Disease
code (ICD-9)-25801) who had attended the Mayo Clinic, Roche-
ster, MN, from 1997 to 2014. Electronic medical records were
assessed for demographic and clinical data regarding PD-NETs
including biochemical testing, radiological imaging, surgical pro-
cedure, associated surgical complications and pathology results.
Diagnosis of MEN-1
In keeping with current clinical guidelines, the diagnosis of
MEN-1 was made in patients who met one of the following cri-
teria: 1. the presence of two or more MEN-1-associated endo-
crine tumours; 2. the occurrence of a MEN-1-associated tumour
in a patient with a family history of MEN-1; and 3. the identifi-
cation of a germline MEN-1 mutation.9
PD-NET diagnosis
A diagnosis of Zollinger–Ellison syndrome (ZES) was based on
the presence of typical hypergastrinaemia symptoms (e.g. gastric
ulceration) and the presence of an elevated gastrin level. The
diagnosis of an insulinoma was based on the confirmation of
Whipple’s triad followed by biochemical confirmation of
endogenous hyperinsulinism.20 The diagnosis of a VIPoma or a
glucagonoma was based on symptoms and VIP levels or a gluca-
gon level ≥2 times the upper limit of normal. A nonfunctioning
PD-PNET diagnosis was based on the presence of a pancreatic
tumour in the absence of a hormonal syndrome. Metastasis was
defined as tumour deposits in lymph nodes or liver seen on
radiological imaging and/or on pathology.
Treatment of PD-NET
Treatment modalities (active surveillance or surgery) for PD-
NETs were based on the clinical assessment of the treating
physician in the context of the values and preference of each
patient and in keeping with current and previous guidelines.9,21
Generally, surgery was recommended when symptoms of hyper-
gastrinaemia failed to respond to medical management (includ-
ing proton pump inhibitors and/or H2 receptor antagonists at
recommended manufacturer doses or higher) or when the lar-
gest PD-NET approached 2 cm in diameter. Active surveillance
was recommended when the tumour was <1 cm in diameter.
For PD-NET between 1 and 2 cm in size, the risks and benefits
of surgery vs observation were discussed with the patient.
Enucleation was performed if a solitary tumour was identified
and was >3 mm from the pancreatic duct. Distal pancreatec-
tomy was the treatment of choice with or without enucleation if
there were more than one tumour present in the distal pancreas.
In the setting of gastrinomas, duodenotomy with excision of
identified tumours was performed or a pancreaticoduodenec-
tomy was performed when head of pancreas lesions were identi-
fied. Liver metastases, when present, were either resected or
treated with radiofrequency ablation if feasible.
Tumour growth
Among those who did not have surgery and had nonfunctioning
PD-NETs, the annual rate of PD-NET growth was calculated.
Functioning PD-NETs were not assessed for tumour growth as
insulinomas are primarily resected, and a majority of gastrinomas
are duodenal making size assessment and source of metastases
challenging. Tumour growth was assessed by documenting the
rate of change in diameter (cm/year) of the largest tumour in
those who had no metastasis at baseline and had the same imaging
modality performed at least twice separated by at least a year. If
more than one scan was performed on follow-up, the first and the
last were used for comparison. Direct comparison of largest
tumour size was performed by the reporting radiologist.
Statistical analyses
Categorical variables were summarized as percentages and con-
tinuous variables were expressed as a mean and standard devia-
tion when normally distributed; otherwise, median values with
interquartile range (IQR) are presented. For survival analysis,
the time of first surgery at Mayo Clinic (expressed in years) was
considered as time zero and patients were followed until death
or last contact. Survival probability was analysed using the
Kaplan–Meier method, and comparisons between groups
assessed using the log-rank test. Logistic regression was used to
assess for predictors of metastasis at surgery including age, sex,
tumour size and tumour type in a univariate model. Cox model
was used to assess predictors of mortality after surgery including
age, sex, tumour size [as a continuous variable and as a binary
variable (tumours <2 cm compared to tumours ≥2 cm and
tumours <3 cm compared to tumours ≥3 cm)], tumour type
and the presence of metastasis at surgery in a univariate model.
The category ‘other’ was excluded from the variable tumour type
as there was only one patient with this and was deemed too
small for comparison. Differences with a significance level
P < 005 were considered to be statistically significant. Statistical
analysis was performed using JMP statistical package.
Results
During the study period (1997–2014), 287 patients who
attended the Mayo Clinic had a diagnosis of MEN-1. The major-
ity were women (n = 167, 58%) with an average age at diagnosis
of MEN-1 of 37 (17) years (Table 1). The most common clini-
cal manifestation of MEN-1 was primary hyperparathyroidism
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(n = 255, 89%) followed by PD-NETs (n = 199, 69%). There
were 217 PD-NETs identified in 199 individuals, and most of
which were nonfunctioning PD-PNETs (110/217, 55%). Among
functioning PD-NETs, gastrinomas (n = 73/107, 68%) were the
most common followed by insulinomas (30/107, 28%), and
VIPomas/glucagonoma (4/107, 4%) (Fig. 1). The average age at
diagnosis of a PD-NET was 42 (14) years. Overall, 43 (15%)
individuals with MEN-1 died. The cause of death was known in
26 (60%), 21/26 (81%) were MEN-1 related and 17/21 (65%) of
which were due to metastatic PD-NET.
Surgical management of PD-NET
Surgery was performed in 128 (64%) patients of which 90
(70%) had their primary surgery performed at Mayo Clinic
(Fig. 2). The surgical procedures performed for treatment of
PD-NET among those who had their primary surgery at Mayo
Clinic are presented in Table 2. There were no surgery-related
deaths. Surgical procedure-related complications occurred in 23
(26%) patients. The most common complication was a pancre-
atic leak which occurred postoperatively in 12 (13%) patients
(Table 3). Diabetes developed postoperatively in nine (10%)
patients with six requiring insulin.
Among those who had their first surgery at Mayo Clinic, the
median size of the largest tumour was 23 cm (range, 03–
25 cm) and the average age at diagnosis of PD-NET was
39 years (14) [see Table 2 for information according to
tumour subtype]. Metastases were present at surgery in 31%
(28/90) of patients (lymph nodes, n = 11; liver, n = 14; both
liver and lymph nodes, n = 3). Metastases present at surgery
were seen in five of nine patients who had subcentimetre PD-
NETs (i.e. tumours <1 cm). There was no association between
sex or size of the largest tumour at surgery and the presence of
metastasis (Table 4). For each year older a patient was at the
time of surgery, the odds of metastasis increased by 6%. The
odds of metastasis at surgery differed by tumour type with
metastatic disease more likely in gastrinomas compared to non-
functioning PD-NETs or insulinomas (P = 0043); however,
given that there were only four events, this needs to be
interpreted accordingly.
Among those who had no metastasis identified at surgery, the
median tumour size was 24 cm (18–33 cm) and 5/62 (8%)
developed metastasis with an average time to metastasis develop-
ment of 148 years. Age, sex and tumour size were not associ-
ated with the risk of metastasis after surgery; however, given
that there were only five events, this needs to be interpreted
accordingly.
The median postoperative follow-up for all of those patients
who had their first surgery at Mayo Clinic was 8 years (IQR,
3–38 years). During follow-up in those who had surgery at
Mayo Clinic, 13 (14%) died (non-functioning PD-NET, six;
gastrinoma, three; insulinoma, three; glucagonoma, one). The
cause of death was known in nine (70%) with seven (78%)
attributable to MEN-1-related causes [six due to metastatic
PD-NET (four nonfunctioning tumours, one gastrinoma and
one VIPoma) and one metastatic thymic carcinoid]. The mean
age of death was 51 (9) years. The probability of survival
after surgery in those with metastases at surgery compared to
Table 1. MEN-1 cohort demographics and mortality
Characteristics Patients (n = 287)
Mean age at diagnosis of MEN-1, years  SD 37  17
Mean age of diagnosis of PD-NET, years  SD 42  14
Female 167 (58%)
Other manifestations of MEN-1
Primary HPT 255 (89%)
Pituitary tumour 139 (48%)
Adrenal mass 37 (13%)
Bronchial/thymic NET 24 (8%)
Died 43 (15%)
HPT, hyperparathyroidism; MEN-1, multiple endocrine neoplasia type 1;
NET, neuroendocrine tumour; PD, pancreaticoduodenal.
Fig. 1 Patient identification flow diagram. Abbreviations: MEN-1,
multiple endocrine neoplasia type 1; n, number of patients; NF,
nonfunctioning; NET= neuroendocrine tumour; NF= nonfunctioning;
PD= pancreaticoduodenal.
Fig. 2 Treatment received according to type of pancreaticoduodenal
neuroendocrine tumour. Brackets indicate percentage that had surgery.
Abbreviations: NF, nonfunctioning; PD, pancreaticoduodenal; NET,
neuroendocrine tumour.
© 2016 John Wiley & Sons Ltd
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those without metastasis at surgery was not statistically differ-
ent (HR: 22, 95% CI: 07–66; P = 017). In addition, the
risk of death was not significantly increased in those who
developed metastasis following surgery compared to those who
did not or with increasing tumour size or tumours ≥2 cm
(Table 3). Studies suggest that the risk of metastasis is
increased among those with gastrinomas ≥3 cm22; therefore,
we assessed mortality risk in those who had surgery for a
PD-NET and had a tumour ≥3cm compared to those with
tumours <3 cm and found that it was increased (HR: 168,
95% CI: 326–30769; P = 00001).
Nonsurgical management of PD-NET
Of the 199 patients with a PD-NET, 70 had active surveillance
(nonfunctioning PD-NET, 43; gastrinoma, 26; and one
Table 2. Patient demographics, tumour characteristics and surgical complications of those who had surgery at Mayo Clinic
NF-PD-NET (n = 40) Gastrinoma (n = 30) Insulinoma (n = 19) Other (n = 1) All (n = 90)
Mean age at diagnosis of PD-NET 36  12 45  11 40  15 38 357  14
Female 20 (50%) 19 (63%) 20 (50%) 0 48 (53%)
Median size, cm (IQR) 25 (19–415) 2 (1–3) 25 (17–395) 95 24 (145–385)
Mets at surgery 8 (20%) 15 (50%) 4 (20%) 1 (100%) 28 (31%)
Died 6 (15%) 3 (10%) 3 (16%) 1 (100%) 13 (14%)
Surgical procedures
DP 34 8 14 1 57
DP + enucleation/duodenotomy 3* 9 3 15
Enucleation 7 1 8
Whipple’s 1 1
PPPD 2† 2 4
Duodenotomy 3 3
Ethanol ablation 1 1 2
DP, distal pancreatectomy; IQR, interquartile range; mets, metastatic disease; NF, nonfunctioning; PD, pancreaticoduodenal; NET, neuroendocrine
tumour; PPPD, pylorus preserving pancreatoduodentomy;
*PPPD, DP, enucleation and ethanol ablation in one patient.
†PPPD, enucleation and DP in one patient.
Table 3. Patient important outcomes during long-term follow-up of patients with MEN-1 and PD-NET*
Intervention
Presence of metastasis
at surgery
Developed
mets after
surgery† Mortality†
MEN-1-related
Death (unknown
cause of death) Surgical complications
Surgery (n = 90) Present (n = 28) (31%) 14 (50%) 6 (21%) 4 (1)‡ Procedural-related complications: 23/90 (25%)
Pancreatic Leak, n = 12
Ileus/obstruction, n = 8
Infection, n = 4
Ventral hernia, n = 1
Anastomotic leak, n = 1
Thalamic haemorrhage, n = 1
Nonprocedural-related complications:
Diabetes, 9/90 (10%)
Absent (n = 62) (69%) 5 (8%) 7 (11%) 3 (4)
Presence of mets at
baseline evaluation
Developed
mets during
follow-up† Mortality†
MEN-1-related
Death (unknown
cause of death) Clinical behaviour during follow-up
Active surveillance (n = 70) Present (n = 22) (31%) NA 8 (36%) 6 (2) NA
Absent (n = 48) (69%) 0 (0%) 4 (8%) 0 (4) Growth 002 cm/year (013–04 cm)
mets, metastatic disease; NA, not applicable;
*Groups are not directly comparable due to unmatched prognosis at baseline.
†Median follow-up with metastasis: 8 years; without metastasis: 9 years; active surveillance without metastasis: 7 years.
‡In one patient, death was due to intra-abdominal abscess.
© 2016 John Wiley & Sons Ltd
Clinical Endocrinology (2017), 86, 199–206
202 D. Donegan et al.
insulinoma). The average age of PD-NET diagnosis was 46
(15), and 48 (53%) were female. The reasons for nonsurgical
management include small/stable (n = 28), inoperable (n = 21)
or managed medically (n = 13) tumours; advised to have sur-
gery, but lost to follow-up (n = 4); and those who did not have
surgery for other reasons (metastatic breast cancer, n = 1; lost to
follow-up, n = 1 up and awaiting adequate weight loss, n = 2).
Surgery was not performed in 22 (31%) patients with PD-NET
tumour as 21 were deemed inoperable in the setting of meta-
static PD-NET and one individual did not have surgery due to
metastatic breast cancer. The most common reason for surveil-
lance was the presence of small (<2 cm) stable tumours and, in
the case of gastrinomas, effective medical treatment.
Annual tumour growth was calculated in 21 patients who par-
ticipated in active surveillance and had nonfunctioning PD-
NETs. Tumour growth among these patients was assessed using
CT abdomen (n = 15), endoscopic ultrasound (n = 5) or MRI
abdomen (n = 1). The median tumour growth per year was
found to be 002 cm with a range of 013 to 04 cm/year.
Among those without metastatic disease who were observed/
medically managed, four (7%) died at a median age of 77
(range, 51–89) years. The cause of death was dementia in one
and unknown in three.
Discussion
PD-NETs are common in patients with MEN-1, yet optimal treat-
ment strategies remain uncertain given the lack of clarity between
the risks, benefits and timing of surgical intervention. In this ret-
rospective study of a large cohort of patients with MEN-1
(n = 287), we showed that among those in whom the cause of
death was known, PD-NETs are the most common cause of MEN-
1-related deaths. In addition, in patients who underwent surgical
treatment for PD-NET (median tumour size 23 cm and with
30% having metastatic disease at baseline), the presence of metas-
tasis at surgery was not predicted by tumour size. In fact, meta-
static disease was seen in some patients with primary tumours
measuring less than 1 cm. In this group, 14% of the patients died
during a median follow-up of 8 years with increased risk of death
in those with tumours >3 cm (65% of the known causes, due to
MEN-1). Moreover, in patients who did not have surgical inter-
vention (e.g. small tumours and symptomatically controlled gas-
trinomas) and were followed with active surveillance 8% died
during follow-up [median time of follow-up 7 years (range,
2–135)] and none developed metastases.
Our study adds to the body of evidence suggesting that the
most common cause of MEN-1-related deaths is metastatic PD-
Table 4. Predictors of patient important outcomes in patients with PD-NET and MEN-1 who underwent surgical intervention
Outcome (n/total) Predictor P value Estimate (CI) OR (CI)
Metastasis at the time
surgery (28/90)
Age (years) 0023 006 (002–01) 106 (102–11)
Sex (female) 034 022 (023–068) 15 (062–382)
Tumour size (cm) 088 001 (015–015) 13 (02–46)
Tumour type†
NF-PD-NET
Gastrinoma
insulinoma
00074
053 (14 to 037)
099 (035–167)
Reference
NF vs gastrinoma
012 (16–137)
Gastrinoma vs insulin
429 (122–1787)
NF vs insulinoma
094 (025–396)
Outcome (n/total) Predictor P value Estimate (CI) HR (CI)
Development of metastasis
after surgery (5/62)*
Age (years) 019 0042 (002–01) 104 (098–11)
Sex (female) 067 019 (071–121) 148 (024–1129)
Tumour size (cm) 077 0025 (025–015) 103 (078–116)
Mortality (13/90) Age (years) 035 002 (002–007) 102 (098–107)
Sex (female) 077 01 (066–045) 121 (04 – 378)
Tumour size (cm) 0098 008 (001–014) 108 (098–115)
Tumour >3 cm 00001 114 (059–286) 168 (326–30769)
Tumour type†
NF-PD-NET
Gastrinoma
insulinoma
051
046 (036–130)
007 (108–079)
Reference
NF vs gastrinoma
17 (044–799)
Gastrinoma vs insulinoma
06 (013–23)
NF vs insulinoma
234 (054–134)
Metastasis at surgery 017 039 (018–094) 22 (07–66)
MEN-1, multiple endocrine neoplasia type 1; n, number of patients with reported outcome; NET = neuroendocrine tumour; NF= nonfunctioning;
PD= pancreaticoduodenal.
*Total of 62 patients did not have metastasis at surgery.
†Excluding one patient who had a VIPoma as this group was felt to be too small for comparison.
© 2016 John Wiley & Sons Ltd
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NET resulting in premature death.5,6,13 We found that 65% of
MEN-1 patients in whom the cause of death was known were
attributable to metastatic PD-NET. In addition, the mean age of
death in those who had surgery was 51 years of age comparable
to a cohort of MEN-1 patients treated at the National Institute
of Health (NIH) which was 55 years (106 patients with a mean
follow-up of 245 years)6 and remains lower than the average
US national average of 788 years.
Due to this association between PD-NET and mortality,
many groups advocate for early detection and treatment to
prevent metastasis and decrease mortality.23–25 Among those
with PD-NET who are surgical candidates, considering surgery
early may be beneficial as we showed that for every year older,
the presence of metastasis increased by 6%. On the other hand,
limitations of the available evidence (small sample size, selec-
tion bias, short duration of follow-up, heterogeneity in popula-
tions and treatment) and concerns regarding the morbidity,
economical and emotional burden of early and aggressive treat-
ment strategies add complexity to our treatment decisions.
Given that MEN-1 is a genetic condition that predisposes
patients to tumour formation, the risk of developing a new
PD-NET remains when limited resections are performed lead-
ing some to advocate for early aggressive surgery with the goals
of reducing recurrence and mortality.26 This however is at the
expense of significant morbidity including exocrine and endo-
crine pancreatic insufficiency as well as worsening of quality of
life.27 Even though distal pancreatectomy was the most com-
mon procedure performed in our study and was not associated
with perioperative mortality, 26% of patients who had surgery
developed a surgical complication. This complication rate is
comparable to other MEN-1-related cohorts with complication
rates reported to be as high as 58% and 21% in non-MEN-1
studies.14,28,29 Diabetes developed in 10% of patients, again this
is comparable to other studies with rates reported to be as
high as 34%.30,31 Therefore, the need, timing and extent of
these surgical interventions need to be weighed against the
potential benefits, the context, and the values and preferences
of the patient.
Determinants of aggressive PD-NET such as malignant poten-
tial and rapid growth may help stratify patients according to
their risk of early mortality. Such markers would allow clinicians
to tailor treatment strategies according to risk with early and
aggressive surgery for those patients at greatest risk. The param-
eters examined here were not predictive of such risk. While
there remains no genotype–phenotype correlation, mutations in
the JunD or CHES1 interacting domain have been associated
with a higher risk of death.14,16 In addition, higher Ki67, CK19
and C-KIT levels in nonhereditary PD-NET have been associated
with decreased survival probability, but this association has not
been assessed specifically in MEN-1.32,33 These mutations and
markers were not examined in this study.
Tumour size has been associated with metastasis in some
studies, and as such, it has been generally accepted that surgery
be performed in tumours >2 cm.18 Given that tumour size and
identification of metastasis is best assessed pathologically, we
analysed this association in those who had surgery. We found
no association between tumour size and metastases at surgery or
during follow-up, results that were similar to those of Lopez
et al. who studied 16 patients with non-functioning PD-NET
with a median follow-up of 109 months. The risk of death after
surgery, however, was noted to be significantly increased among
those with tumours >3 cm (P = 00001). Given that the average
rate of tumour growth in our nonsurgical group on active
surveillance and in whom comparative imaging was available
was 002 cm per year (013–04 cm), this suggests a more
indolent course in some tumours. Therefore, identifying aggres-
sive tumours traits and treating these early surgically may
decrease mortality while minimizing morbidity in those who
would have had a more indolent course. This also highlights the
need for co-ordinated care in a multidisciplinary centre to pro-
vide appropriate follow-up and surgical intervention when
needed.
There are several strengths and limitations to our study. Given
the rarity of this condition, prospective studies remain challeng-
ing and our study includes a large cohort of MEN-1 patients
cared for at a single centre reducing heterogeneity. In addition,
the duration of follow-up was long. This was a retrospective
study and is therefore subject to selection bias, especially among
those who had PD-NETs that were 1–2 cm in size where inter-
vention can be driven by patient preference. Also as a single cen-
tre study, the results may not apply to patients seen in other
settings. Assessment of the cause of death is limited as the cause
of death could only be identified in 60% of those who died.
Review of the literature, however, would suggest that our find-
ings are comparable to other series. Imaging studies are not as
sensitive as surgical pathology for detecting metastasis, and
therefore, among those who did not have surgery, it is likely that
the absence of metastasis is overestimated. Nevertheless, the
mean age of death in this group was 77 years, and therefore, if
metastases were present, they were unlikely to be clinically
important.
Finally, it is likely that the real benefit of surgery is masked in
the study due to lack of an adequate comparative group and
selection bias due to our observational retrospective design.
While the mean age of death in those who had surgery does not
appear to have improved, there were only 13 deaths in the surgi-
cal cohort, six of which were PD-NET related. Therefore, it is
difficult to assess the effect surgery has on number of deaths,
symptom reduction and quality of life given the systemic nature
of the disease.
Conclusion
PD-NETs are associated with increased mortality in patients
with MEN-1. A subgroup of patients with MEN-1, however,
have PD-NETs that appear to have indolent behaviour; given
the high morbidity associated with surgical intervention identifi-
cation of factors which predict aggressive behaviour (mortality,
metastasis) to direct therapy will help personalize future care for
patients with MEN-1. In the interim, the data available from this
study suggest that patients and clinicians should discuss the
potential benefits and harms associated with different treatment
© 2016 John Wiley & Sons Ltd
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options resulting in a treatment decision best suited to the
patients’ particular context.
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